
    
      The main objective of the study is to prove the superiority of the QazCovid-in®-vaccine
      inactivated against COVID-19 in comparison with placebo in terms of seroconversion (the
      proportion of persons with a fourfold or higher increase in antibody titers to SARS-CoV-2) on
      the 21st, 42nd day, 90th and 180th days after vaccination.

      To evaluate the immunogenicity of the QazCovid-in® vaccine inactivated against COVID-19
      versus placebo.

      Evaluate vaccine efficacy.

      Evaluate the safety of vaccine versus placebo.
    
  